Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY RE-HIT: ianalumab re-treatment in adults with relapsed primary immune thrombocytopenia or warm autoimmune hemolytic anemia previously benefiting from ianalumab
jRCT2041250181Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of ianalumab in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) (2 arms), sponsored by Novartis. Primary endpoints: Treatment failure free and Durable response. Started Oct 2026; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on jRCT2041250181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250181.